doxycycline
Commercial- Indications
- Rosacea, Acne
Company intelligence / Profile preview
CollaGenex developed Oracea®, the first FDA-approved systemic therapy for rosacea. Clinical trials showed significant reduction in inflammatory lesions compared to placebo. Other pipeline products included incyclinide for acne/rosacea and COL‑118 for erythema of rosacea[6][7]. The company also marketed Periostat® for periodontitis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CollaGenex Pharmaceuticals.